BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23568978)

  • 1. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
    Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
    Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
    Chen WM; Wei KL; Chen YS; Chang PJ; Tung SY; Chang TS; Huang HC; Shen CH; Hsieh YY; Wu CS
    World J Surg Oncol; 2016 May; 14():140. PubMed ID: 27142076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study.
    Navaneethan U; Gutierrez NG; Jegadeesan R; Venkatesh PG; Poptic E; Liu X; Sanaka MR; Jang S; Vargo JJ; Parsi MA
    Dig Dis Sci; 2013 Oct; 58(10):2986-92. PubMed ID: 23828141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma.
    Chen J; Liang J; Xu B; Liang J; Ma M; Wang Z; Zeng G; Xu Q; Liang L; Lai J; Huang L
    J Gastrointest Cancer; 2024 Jun; 55(2):800-808. PubMed ID: 38280173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
    Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
    BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test.
    Wang HJ; He XJ; Ma YY; Jiang XT; Xia YJ; Ye ZY; Zhao ZS; Tao HQ
    Anat Rec (Hoboken); 2010 Nov; 293(11):1855-63. PubMed ID: 20730863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas.
    Kaur S; Baine MJ; Guha S; Ochi N; Chakraborty S; Mallya K; Thomas C; Crook J; Wallace MB; Woodward TA; Jain M; Singh S; Sasson AR; Skinner V; Raimondo M; Batra SK
    Pancreas; 2013 Apr; 42(3):494-501. PubMed ID: 23146921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volatile Organic Compounds in Urine for Noninvasive Diagnosis of Malignant Biliary Strictures: A Pilot Study.
    Navaneethan U; Parsi MA; Lourdusamy D; Grove D; Sanaka MR; Hammel JP; Vargo JJ; Dweik RA
    Dig Dis Sci; 2015 Jul; 60(7):2150-7. PubMed ID: 25708900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses.
    Farina A; Dumonceau JM; Antinori P; Annessi-Ramseyer I; Frossard JL; Hochstrasser DF; Delhaye M; Lescuyer P
    Biochim Biophys Acta; 2014 May; 1844(5):1018-25. PubMed ID: 23806607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody array-based proteomic screening of novel biomarkers in malignant biliary stricture.
    Qin WH; Liu JT; Wang SP; Yang ZS; Wang KK; Hu B
    Cancer Biomark; 2022; 33(3):359-368. PubMed ID: 34542063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of bile soluble B7H3 for the diagnosis of malignant biliary strictures: Results of a retrospective study.
    Liu Y; Cheng C; Bai L; Yao F; Shi S; Zhang Y
    Surg Oncol; 2019 Mar; 28():195-200. PubMed ID: 30851900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
    J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP.
    Park MS; Kim TK; Kim KW; Park SW; Lee JK; Kim JS; Lee JH; Kim KA; Kim AY; Kim PN; Lee MG; Ha HK
    Radiology; 2004 Oct; 233(1):234-40. PubMed ID: 15333766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.
    Lindberg B; Arnelo U; Bergquist A; Thörne A; Hjerpe A; Granqvist S; Hansson LO; Tribukait B; Persson B; Broomé U
    Endoscopy; 2002 Nov; 34(11):909-16. PubMed ID: 12430077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.